Alteraciones adquiridas de la coagulación

  1. Martitegui, X. Martín
  2. Irulegui, G. Iruin
  3. Quintana, A. Moretó
  4. Aisa, C. Sierra
  5. Díez, E. Amutio
  6. García-Ruiz, J.C.
Zeitschrift:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Datum der Publikation: 2016

Serie: 12

Nummer: 22

Seiten: 1275-1283

Art: Artikel

DOI: 10.1016/J.MED.2016.10.021 DIALNET GOOGLE SCHOLAR

Andere Publikationen in: Medicine: Programa de Formación Médica Continuada Acreditado

Ziele für nachhaltige Entwicklung

Zusammenfassung

Abstract Background Hypocoagulabilities secondary to acquired clotting defects are frequently observed processes in clinical practice. In this chapter we will discuss firstly the acquired coagulopathies, and then the complex haemostatic deficiencies. Aetiology Usually these disorders are produced by a defect or deficit of clotting factors synthesis, or by an excessive consumption of them. These syndromes are also induced by the treatment with certain drugs or the spontaneous emergence of neutralizing antibodies, and it is not uncommon the simultaneous combination of several factors. Symtoms and diagnosis Clinically, these alterations cause varying degrees of haemorrhage in which laboratory results aren’t always correlated with clinical severity. Clinical suspicion is vital to diagnose correctly the disease. Treatment The treatment, always individualized, will depend on the underlying cause of the haemostatic alteration that causes the haemorrhage.

Bibliographische Referenzen

  • Shearer MJ. Vitamin K. Lancet. 1995; 345:229.
  • Furie B, Furie BC. Molecular basis of vitamin K-dependent gamma-car-boxylation. Blood. 1990;75:1753-62.
  • Martinez-Brotons F, Domenech P. Hipocoagulabilidades adquiridas. Sín-dromes de coagulación intravascular diseminada. Deficiencias complejas de la hemostasia. En: Sans Sabrafen J, editor. Hematología clínica. Barce-lona: Elsevier; 2006. p. 745-56.
  • Volpe JJ. Intracranial hemorrhage in early infancy-renewed importance of vitamin K deficiency. Pediatr Neurol. 2014; 50:545.
  • Taylor FB J, Toh CH, Hoots WK, Wada H, Levi M; Scientific Subcomittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated Intravascular coagulation. Thromb Hae-most. 2001;86:1327-30.
  • Thachil J, Toh CH. Current concepts in the management of disseminated intravascular coagulation. Thromb Research. 2012;129:S54-9.
  • Liebman HA, Weitz IC. Disseminated intravascular coagulation. En Hoffman R, editor. Hematology, basic principles and practice. Philadel-phia: Elsevier; 2009. p. 1999-2009.
  • Kitchens Kruse-Jarres R. Acquired bleeding disorders in the el-derly. Hematology Am Soc Hematol Educ Program. 2015;231-6.
  • Kitchens CS. Thrombocytopenia and thrombosis in disseminated intra-vascular coagulation (DIC). Hematology Am Soc Hematol Educ Pro-gram. 2009;240-6.
  • Dreyfus M, Magny JF, Bridey F, Schwarz HP, Planché C, Dehan M, et al. Treatment of homozygous protein C deficiency and neonatal purpuraful-minans with a purified protein C concentrate. N Engl J Med. 1991;325: 1565-8.
  • Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagula-tion. Br J Haematol. 2009;145: 24-33.
  • Levi M. Diagnosis and treatment of disseminated intravascular coagula-tion. Int J Lab Hematol. 2014;36:228-36.
  • Feinsten DI. Lupus anticoagulant and adcquired inhibitors of blood coa-gulation. En: Hoffman R, editor. Hematology, basic principles and prac-tice. Philadelphia: Elsevier; 2009. p 1979-97.
  • Franchini M, Mannucci PM. Aquired haemophilia A: a 2013 update. Thromb Haemost. 2013;110:1114-20.
  • Collins PW, Hirsch S, Baglin TP, Dolan G, Hanley J, Makris M, et al. Acquired hemophilia A in the United Kingdom: a 2-year national survei-llance study by the United Kingdom Haemophilia Centre Doctors’ Or-ganisation. Blood. 2007;109:1870-7.
  • Franchini M, Lippi G. Acquired factor VIII inhibitors. Blood. 2008;112: 250-5.
  • Delgado J, Jiménez-Yuste V, Hernández-Navarro F, Villar A. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol. 2003;121:21-35.
  • Collins PW. Treatment of acquired hemophilia A. J Thromb Haemost 2007;5:893-900.
  • Collins P, Baudo F, Knoebl P, Levesqué H, Nemes L, Pellegrini F, et al. Immunosuppression for acquired hemophilia A: results from the Euro-pean Acquired Haemophilia Registry (EACH2). Blood. 2012;120:47-55.
  • Tiede A, Rand JH, Budde U, Ganser A, Federici AB. How I treat the acquired von Willebrand syndrome. Blood. 2011;117:6777-85.
  • Franchini M, Lippi G. Acquired Von Willebrand Syndrome: an update. Am J Hematol. 2007; 82:386-75.
  • Federici AB, Rand JH, Bucciarelli P, Budde U, van Genderen PJ, Mohri H, et al. Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost. 2000;84:345-9.
  • Tiede A, Priesack J, Werwitzke S, Bohlmann K, Oortwijn B, Lenting P, et al. Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single centre cohort study. J Thromb Haemost. 2008;6:569-76.
  • Haberichter SL, Castaman G, Budde U, Peake I, Goodeve A, Rodeghiero F, et al. Identification of type 1 von Willebrand disease patients with redu-ced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and ma-nagement of type 1 VWD (MCMDM-1VWD). Blood. 2008;111:4979-85.
  • Van Schooten CJ, Denis CV, Lisman T, Eikenboom JC, Leebeek FW, Goudemand J, et al. Variations in glycosylation of von Willebrand factor with O-linked sialylated T antigen are associated with its plasma levels. Blood. 2007;109: 2430-7.
  • Mohri H, Motomura S, Kanamori H, Matsuzaki M, Watanabe S, Maruta A, et al. Clinical significance of inhibitors in acquired von Willebrand syndrome. Blood. 1998;91:3623-9.
  • Lollar P. Pathogenic antibodies to coagulation factors. Part II. Fibrino-gen, prothrombin, thrombin, factor V, factor XI, factor XII, factor XIII, the protein C system and von Willebrand factor. J Thromb Haemost. 2005;3:1385-91.
  • Ortel TL, Charles LA, Keller FG, Marcom PK, Oldham HN, Kane WH, et al. Topical thrombin and acquired coagulation factor inhibitors: clinical spectrum and laboratory diagnosis. Am J Hematol. 1994; 45:128.
  • Kulovich JL. Coagulopathy in liver disease: a balancing act. Hematology Am Soc Hematol Educ Program. 2015;243-249.
  • Roberts LN, Patel K, Arya R. Haemostasis and thrombosis in liver disea-se. Br J Haematol. 2009;148:507-21.
  • Paramo JA. Hemostasia, hemorragia y trombosis en cirugía. Cir Esp. 2009;85:2-6.
  • Suarez M, Sangro B, Herrero JI, Picardi A, Paramo JA, Quiroga J, et al. Effectiveness of apoprotein in orthotopic liver transplantation. Semin Thromb Haemost. 1993;19:292-6.
  • Páramo JA, Rifón J, Rocha E. Patogénesis y tratamiento de los cambios hemostáticos en cirugía extracorpórea. Sangre. 1993; 38:225-31.
Fuente de los datos: Dialnet